IN THE UNITED STATES BANKRUPTCY COURT
FOR THE EASTERN DISTRICT OF MISSOURI

In re	)	Chapter 11
	)	
THE CHRISTY REFRACTORIES COMPANY, LLC,	)	Case No. 08-48541
	)	
Debtor.	)	Honorable Kathy A. Surratt-States

NOTICE OF FILING

PLEASE TAKE NOTICE that, on April 28, 2023, the **Christy Refractories Asbestos Personal Injury Trust Special-Purpose Financial Statements and Report of Independent Auditors for the Years Ended December 31, 2022 and 2021 and Related Information** were filed electronically by FrankGecker LLP with the United States Bankruptcy Court for the Eastern District of Missouri, Thomas F. Eagleton United States Courthouse, 111 South 10th Street, St. Louis, Missouri 63102.

Dated: April 28, 2023

CHRISTY REFRACTORIES ASBESTOS PERSONAL INJURY TRUST

By: */s/ Joseph D. Frank*
One of its attorneys

Joseph D. Frank (IL No. 6216085)
FRANKGECKER LLP
1327 W. Washington Blvd., Suite 5 G-H
Chicago, Illinois 60607
Phone: (312) 276-1400
Fax: (312) 276-0035
jfrank@fgllp.com

{CHRISTY/001/00053663.DOC/6}

CERTIFICATE OF SERVICE

I, Joseph D. Frank, an attorney, hereby certify that, on **April 28, 2023**, a true and correct copy of the **Notice of Filing of the Christy Refractories Asbestos Personal Injury Trust Special-Purpose Financial Statements and Report of Independent Auditors for the Years Ended December 31, 2022 and 2021 and Related Information** was filed electronically. Notice of the filing was automatically sent to all parties who are currently on the Court's Electronic Mail Notice List by operation of the Court's Electronic Filing System. In addition, those parties who did not receive the filing electronically were served via first-class United States mail, postage prepaid, as indicated on the attached Service List.

/s/ Joseph D. Frank

Mailing Information for Case 08-48541

Electronic Mail Notice List

The following is the list of **parties** who are currently on the list to receive email notice/service for this case.

- Bartholomew J. Baumstark baumstark@obrienlawfirm.com; thoron@obrienlawfirm.com
- Joseph D. Frank jfrank@fgllp.com; mmatlock@fgllp.com; csmith@fgllp.com; csucic@fgllp.com; jkleinman@fgllp.com
- Allison E Graves allison.e.graves@gmail.com
- Scott A. Greenberg sgreenberg@sandbergphoenix.com; rhileman@sandbergphoenix.com
- Elizabeth V. Heller elizabeth@ghalaw.com; tjones@ghalaw.com
- Peter D. Kerth pkerth@jenkinskling.com; sshimkus@jenkinskling.com
- Brian James LaFlamme blaflamme@summerscomptonwells.com
- Richard M. Maseles edmoecf@dor.mo.gov
- Office of US Trustee USTPRegion13.SL.ECF@USDOJ.gov
- Robert Woods Phillips rphillips@simmonscooper.com
- David P. Stoeberl dps@carmodymacdonald.com; ksg@carmodymacdonald.com;arb@carmodymacdonald.com; kz@carmodymacdonald.com
- Laura Toledo ltoledo@lathropgage.com, jbuchheit@lathropgage.com
- David M. Unseth dmunseth@bclplaw.com
- Brian C. Walsh bcwecfnotices@gmail.com
- David A. Warfield dwarfield@thompsoncoburn.com

{CHRISTY/001/00053663.DOC/6}

SERVICE LIST

CHRISTY REFRACTORIES ASBESTOS PERSONAL INJURY TRUST

Via Email
Alan B. Rich
LAW OFFICE OF ALAN B. RICH
7324 Gaston Avenue
Suite 124, LB430
Dallas, TX 75214
christy@alanrichlaw.com

Via Email
Andrew A. Kress
41 Summit Road
Port Washington, New York 11050
Andrewka22@outlook.com

Via Email
Robert J. Cooney Jr.
Ryan Linsner
COONEY AND CONWAY
120 North LaSalle Street, 30th Floor
Chicago, Illinois 60602
bcooney@cooneyconway.com
rlinsner@cooneyconway.com

Via Email
Perry J. Browder
Christopher Guinn
SIMMONS HANLY CONROY
One Court Street
Alton, Illinois 62002
pbrowder@simmonsfirm.com
cguinn@simmonsfirm.com

Via Email
Andrew A. O'Brien
Christopher Thoron
O'BRIEN LAW FIRM, P.C.
815 Geyer Avenue
St. Louis, Missouri 63104
obrien@obrienlawfirm.com
thoron@obrienlawfirm.com

Via Email
Fred M. Brody
Julie Chiocca
MORRISON & MORRISON, LTD.
222 S. Riverside Plaza, Suite 2730
Chicago, Illinois 60606
fmb@morrmorr.com
jchiocca@morrmorr.com

Via Email
Kami Quinn
GILBERT LLP
1100 New York Avenue, NW, Suite 700
Washington, D.C. 20005
quinnk@gotofirm.com

Via Email
Harry Lee
STEPTOE & JOHNSON LLP
1330 Connecticut Avenue, N.W.
Washington, D.C. 20036
hlee@steptoe.com

SERVICE LIST

CHRISTY REFRACTORIES ASBESTOS PERSONAL INJURY TRUST

Via Email
Scott Greenberg
Clayton G. Kuhn
SANDBERG, PHOENIX & VON GONTARD, PC
One City Centre, Suite 1500
St. Louis, Missouri 63101
sgreenberg@spvg.com
ckuhn@spvg.com

Via Email
Mark D. Plevin
CROWELL & MORING LLP
1001 Pennsylvania Avenue, N.W.
Washington, D.C. 20004-2595
mplevin@crowell.com;

Via Email
Phil Kosmala
Managing Director
Taiber Kosmala & Associates, LLC
141 W. Jackson Blvd.
Suite 3540
Chicago, IL 60604
philk@taiberkosmala.com

U.S. Mail
The Christy Refractories Company, LLC
4641 McRee Avenue
St. Louis, Missouri 63110

U.S. Mail
WILMINGTON TRUST COMPANY
1100 North Water Street
Wilmington, Delaware 19890

U.S. Mail
JACKSON WALKER L.L.P.
2323 Ross Avenue
Suite 600
Dallas, Texas 75201

{CHRISTY/001/00053663.DOC/6}

Christy Refractories Asbestos Personal Injury Trust

Special-Purpose Financial Statements and Independent Auditor's Report

December 31, 2022 and 2021

CohnReznick
ADVISORY • ASSURANCE • TAX

Christy Refractories Asbestos Personal Injury Trust

Index

	Page
Independent Auditor's Report	2
Special-Purpose Financial Statements	
Special-Purpose Statements of Net Claimants' Equity	4
Special-Purpose Statements of Changes in Net Claimants' Equity	5
Notes to Special-Purpose Financial Statements	6

Independent Auditor's Report

To the Trustee of
Christy Refractories Asbestos Personal Injury Trust

Opinion

We have audited the accompanying special-purpose financial statements of the Christy Refractories Asbestos Personal Injury Trust (the "Trust", organized in the State of Delaware), which comprise the special-purpose statement of net claimants' equity as of December 31, 2022, and the related special-purpose statement of changes in net claimants' equity for the year then ended, and the related notes to the special-purpose financial statements (collectively, the "Financial Statements").

In our opinion, the accompanying Financial Statements present fairly, in all material respects, the net claimants' equity of the Trust as of December 31, 2022, and the changes in net claimants' equity for the year then ended in conformity with the basis of accounting described in Note 2 to the Financial Statements.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America ("GAAS"). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Trust and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide our audit opinion.

Basis of Accounting

We draw attention to Note 2 of the Financial Statements, which describes the basis of accounting. The Financial Statements are prepared on a special-purpose basis of accounting which is a basis of accounting other than accounting principles generally accepted in the United States of America. The special-purpose basis of accounting has been adopted by the Trustee to communicate the amount of equity presently available to fund current and future claims. As a result, the Financial Statements may not be suitable for another purpose. Our opinion is not modified with respect to this matter.

Other Matter - Prior Year Financial Statements

The Financial Statements of the Trust for the year ended December 31, 2021, were audited by BKM Sowan Horan, LLP ("BKM"), whose partners and professional staff joined CohnReznick, LLP as of November 1, 2022. BKM expressed an unmodified opinion on those statements in their report dated April 12, 2022 and included an emphasis of matter indicating that the Trust's Financial Statements were prepared on the special-purpose basis of accounting which is a basis of accounting used to present the amount of equity presently available to current and future claimants.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of these Financial Statements in accordance with the special-purpose basis of accounting; this includes determining that the special-purpose basis of accounting is an acceptable basis for the preparation of the Financial Statements in these circumstances. Management is also responsible for the design, implementation, and maintenance

Published by AsbestosClaims.Law
asbestosclaims.law/library/13793/7

of internal control relevant to the preparation and fair presentation of the Financial Statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the Financial Statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the Financial Statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Trust's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the Financial Statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Trust's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Restriction on Use

This report is intended solely for the information and use of the management of the Trust, the Trustee, the beneficiaries of the Trust and the United States Bankruptcy Court for the Eastern District of Missouri and is not intended to be and should not be used by anyone other than these specified parties. Upon filing with the United States Bankruptcy Court for the Eastern District of Missouri, the report is a matter of public record, which public filing does not expand the list of specified users.

CohnReznick LLP

Dallas, Texas
April 14, 2023

Christy Refractories Asbestos Personal Injury Trust

Special-Purpose Statements of Net Claimants' Equity
December 31, 2022 and 2021

Assets

	2022	2021
Cash and cash equivalents		
Unrestricted	$ 669,343	$ 257,176
Restricted	225,720	284,200
Investments in marketable securities and certificates of deposit	11,764,566	19,115,046
Accrued interest and dividend income	108,464	156,030
Prepaid expenses and other	60,360	58,213
Total assets	$ 12,828,453	$ 19,870,665

Liabilities and Net Claimants' Equity

Accrued expenses	$ 27,669	$ 34,752
Accrued payments to claimants	142,715	111,618
Claims processing deposits	16,100	17,160
Deferred tax liability	-	606,420
Total liabilities	186,484	769,950
Net claimants' equity	$ 12,641,969	$ 19,100,715

See Notes to Special-Purpose Financial Statements.

Christy Refractories Asbestos Personal Injury Trust

Special-Purpose Statements of Changes in Net Claimants' Equity
Years Ended December 31, 2022 and 2021

	2022	2021
Additions		
Interest and dividend income	$ 711,938	$ 785,598
Income tax benefit, net	606,420	-
Filing fees collected on withdrawn claims	1,700	4,740
Net gain on investments in marketable securities, net of management fees, custody fees and bond amortization	-	69,989
Total additions	1,320,058	860,327
Deductions		
Payments to Claimants	5,029,584	569,330
Net loss on investments in marketable securities, net of management fees, custody fees and bond amortization	2,441,212	-
Income tax expense, net	-	116,847
Trustee fees and expenses	79,078	69,994
Accounting fees	58,933	55,238
Trustee annual fee	50,875	50,000
Legal fees	36,057	20,278
Financial consulting fees	18,000	18,000
Insurance expense	17,296	17,336
Audit fees	13,391	14,538
Claims processing fees	16,216	9,132
Delaware Trustee fees and expenses	4,000	4,000
File storage and retrieval fees	3,574	3,540
Future Claimants' Representative fees and expenses	2,625	2,750
Consulting fees	7,462	324
Foreign taxes paid	501	230
Total deductions	7,778,804	951,537
Net decrease in net claimants' equity	(6,458,746)	(91,210)
Net claimants' equity, beginning of year	19,100,715	19,191,925
Net claimants' equity, end of year	$ 12,641,969	$ 19,100,715

See Notes to Special-Purpose Financial Statements.

Christy Refractories Asbestos Personal Injury Trust

Notes to Special-Purpose Financial Statements
December 31, 2022 and 2021

Note 1 - Nature of Trust

Description of Trust

The Christy Refractories Asbestos Personal Injury Trust (the "Trust") was established in accordance with the First Amended Plan of Reorganization (the "Plan"), under Chapter 11 of the United States Bankruptcy Code, of The Christy Refractories Company, LLC ("Christy"). The purpose of the Trust is:

- to assume liability for all present and future personal injury and/or wrongful death claims against Christy and/or its past or present predecessors, subsidiaries, affiliates, officers, directors or employees, arising from exposure to asbestos-containing products for which Christy is directly or indirectly liable;

- to use the Trust's assets and income to pay holders of valid asbestos personal injury claims; and

- to comply in all respects with the requirements for a trust set forth in Section 524(g)(2)(B)(i) of the Bankruptcy Code.

The Trust was established on September 26, 2011, the Effective Date of the Plan ("Effective Date") and is a Qualified Settlement Fund under Internal Revenue Code (the "Code") Section 468B for holders of asbestos personal injury claims ("Qualified Settlement Fund"). The Trust operates as the Christy Refractories Asbestos Personal Injury Trust.

Pursuant to the Plan, Christy and its Affiliates agreed to contributions totaling $2,600,000 to the Trust, including a cash contribution of $600,000 and a Promissory Note of $2,000,000. The Trust received $2,258,565 from Christy, representing both the $600,000 cash payment and $1,658,565 as the prepayment settlement amount in accordance with the terms of the promissory note. The note was deemed paid in full and cancelled. Christy also transferred its rights under insurance policies to the Trust, including $12,250,000 received from a certain insurer. In addition, the Trust received $2,038,862 from Christy's defense counsel, comprised of prepaid settlement funds that were deposited by one of Christy's insurers into Christy's defense counsel's trust account prior to Christy's bankruptcy filing.

During September 2015, the Trust negotiated a settlement with an insurance company with total proceeds of $4,000,000, payable to the Trust in five equal annual payments of $800,000. The balance was paid in full in September 2019.

The Trust is governed by a Trust Agreement and Trust Distribution Procedures ("TDP") that establish the framework and criteria for allowance and payment of Claims by the Trust. The Trust Agreement and TDP were approved by the United States District Court as part of the Plan.

There are eight disease levels specified in the TDP. Each claimant who meets the medical and exposure requirements of the TDP for a particular disease level may apply for expedited review and a specified payment amount (except those involving Lung Cancer 2 - Disease Level VI and all Foreign Claims, as defined in the TDP), which shall only be liquidated pursuant to the Asbestos PI Trust's Individual Review Process. Claimants eligible for expedited review also have an alternative, under the TDP, to submit additional documentation and request a more expansive review of their Claim ("Individual Review Process") in which case claims may be paid within a range of amounts.

The Trust's assets consist primarily of cash and cash equivalents, investments in marketable securities, and certificates of deposit, which, with the earnings (or losses) on such assets, are intended to be totally consumed by the allowance and payment of claims and operation of the Trust. The percentage amount of each allowed claim that will actually be paid will be determined by projections of total allowed Claims and operational expenses of the Trust, on the one hand, and total assets and net earnings (or losses), on the other. The Trust began accepting claims in 2012 and began to pay claims in 2013. Pursuant to the TDP, effective October 18, 2016, the Trust increased the payment percentage from 11% (initial payment percentage) to 40%. Claimants whose claims were liquidated and paid in prior periods received additional payments in November 2016, as provided in the TDP. Pursuant to the TDP, effective October 31, 2022, the Trust increased the payment percentage from 40% to 55%. Claimants whose claims were liquidated and paid in prior periods received additional payments in December 2022, as provided in the TDP. The payment percentage is subject to periodic review and adjustment. The Trustee is a fiduciary to the beneficiaries of the Trust and is responsible for administering the Trust and the Trust's assets in accordance with the Trust Agreement and the Plan.

Termination
The Trust Agreement (Section 8.2) provides that the Trust shall automatically dissolve on the date (the "Dissolution Date") ninety (90) days after the first to occur of the following events:

- The date on which the Trustee decides to dissolve the Trust because (A) the Trustee deems it unlikely that new Claims will be filed against the Trust , (B) all Claims duly filed with the Trust have been liquidated and paid to the extent provided in the Trust Agreement and TDP, or have been disallowed by a final, non-appealable order, to the extent possible based upon the funds available through the Plan, and twelve (12) consecutive months have elapsed during which no new Claims have been filed with the Trust;

- If the Trustee has procured and has in place irrevocable insurance policies and has established claims handling agreements and other necessary arrangements with suitable third parties adequate to discharge all expected remaining obligations and expenses of the Trust in a manner consistent with the Trust Agreement and the TDP, the date on which the Bankruptcy Court enters an order approving such insurance and other arrangements and such order becomes a final order; or

- To the extent that a rule against perpetuities shall be deemed applicable to the Trust, that date which is twenty-one (21) years less ninety-one (91) days after the death of the last survivor of all the descendants of the late Joseph P. Kennedy, Sr., father of the late President John F. Kennedy, living on the date of the Trust Agreement.

On the dissolution date or as soon as reasonably practicable, after the wind-up of the Trust's affairs by the Trustee and payment of all the Trust's liabilities have been provided for as required by applicable law, all remaining assets shall be applied to such charitable purposes, if practicable, which shall be related to the treatment of, research on, or the relief of individuals suffering from asbestos related lung disease or disorders.

Following the dissolution and distribution of the assets of the Trust, the Trust shall terminate and the Trustee shall execute and file a Certificate of Cancellation.

Note 2 - Summary of significant accounting policies

Basis of accounting

The Trust's special-purpose financial statements ("Financial Statements") are prepared using special-purpose accounting methods that differ from accounting principles generally accepted in the United States of America ("GAAP"). The special-purpose accounting methods are being used to better communicate the equity available to satisfy current and future claims. Since the accompanying Financial Statements and transactions are not based upon GAAP, accounting treatment by other parties for these same transactions may differ as to timing and amount. These special-purpose accounting methods and the differences from GAAP are summarized as follows:

- The Financial Statements are prepared using the accrual basis of accounting, except as otherwise described herein.
- The statements of net claimants' equity are not classified, resulting in no separation between current and noncurrent assets.
- These Financial Statements do not include a statement of cash flows.
- Cash and cash equivalents are recorded at cost with accrued interest shown separately.
- The funding received from Christy, certain insurers and defense counsel of Christy, has been recorded directly to net claimants' equity. These funds do not represent taxable income to the Trust. Payments to Claimants are reported as deductions from net claimants' equity and do not represent tax-deductible expenses of the Trust.
- At December 31, 2022 and 2021, the liability for accrued payments to claimants reflected in the statements of net claimants' equity represents unpaid outstanding and accepted offers, respectively. No liability is recorded for future claims filings and filed claims on which no offer has been made. Net claimants' equity represents funding available to pay present and future claims on which no liability has been recorded.
- At December 31, 2022 and 2021, the Trust's investments in marketable debt securities are considered as available for sale. The unrealized holding gains (losses) on these investments are included in net gain on investments in marketable securities, net of management fees, custody fees, and bond amortization on the accompanying statements of changes in net claimants' equity. Under GAAP, the unrealized holding gains (losses) on available for sale investments would be included as a component of net claimants' equity reported as accumulated other comprehensive income (loss). In addition, the Trust's unrealized holding gains (losses) are shown net.

Use of estimates

The preparation of Financial Statements in conformity with the basis of accounting described above, requires the Trust to make estimates and assumptions that affect the reported amounts of certain assets and liabilities and the disclosure of contingent assets and liabilities at the date of the Financial Statements, as well as the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include the fair value of investments and the provision for income taxes. Actual results could differ from those estimates.

Financial instruments
The Trust's financial instruments are cash and cash equivalents, accrued investment income, marketable securities, certificates of deposit, accrued expenses and payments to claimants.

The carrying amount of cash and cash equivalents, accrued investment income and accrued expenses approximate their fair values based on their short-term nature. The carrying amount of payments to claimants approximates fair value based upon management's estimates. The carrying amount of marketable securities and certificates of deposit are based on fair value.

Cash and cash equivalents
The Trust considers all highly-liquid debt instruments purchased with an original maturity value of three months or less to be cash equivalents. Unrestricted cash and cash equivalents at December 31, 2022 and 2021, as follows:

	2022	2021
Money market funds		
Fidelity Government Fund	$ 667,643	$ 141,773
PNC Bank	-	110,663
Filing fee account	1,700	4,740
	$ 669,343	$ 257,176

At December 31, 2022, and 2021, restricted cash represents filing fees received from claimants, which will be refunded if the claim is accepted and retained by the Trust if the claim does not qualify for payment. Also, at December 31, 2022 and 2021, restricted cash includes $209,620 and $267,040, respectively, of funds remaining in the segregated client trust account under the Claims Resolution Agreement. See Note 6.

Concentrations of credit risk
Financial instruments, which potentially subject the Trust to concentrations of credit risk, consist primarily of cash and cash equivalents, investments in marketable securities and certificates of deposit. The Trust maintained its cash and cash equivalents in accounts that are not federally insured but considers them to be of high-credit quality. The Trust has not experienced any losses in such accounts, and it does not believe it is exposed to any significant credit risk.

The Trust's investments are exposed to various risks, such as interest rate, market and credit risk. Due to the level of risk associated with investments, it is at least reasonably possible that significant changes in risks in the near term may materially affect the amounts reported in the Financial Statements. However, the Trust has a formal investment policy of placing investments in high-quality financial institutions.

Investments in marketable securities and related income (loss)
Investments in marketable securities are reported at fair value in the special-purpose statements of net claimants' equity and changes in the fair value of investments, as well as unrealized and realized gains and losses are included in net gain on investments in marketable securities, net of management fees, custody fees and bond amortization reported in the special-purpose statements of changes in net claimants' equity. Purchases and sales of marketable securities are recorded on the trade date. Realized gains and losses on disposals of investments are determined by the specific identification method. Interest and dividend income are recognized on the accrual basis.

Investments considered to be permanently impaired in value are written down to their estimated net realizable value and the write down is recorded as a realized loss on investments. Unrealized losses that are other-than-temporary based upon management's estimates using quantitative and qualitative criteria are recognized as realized investment losses. Actual results could differ from those estimates.

Claims processing deposits
Claims processing deposits represent filing fees collected for each unliquidated claim, which will be refunded by the Trust if the claim is paid.

Net claimants' equity
The Trust, under the adopted special-purpose accounting convention, does not record the liability for future claims expected to be filed over the life of the Trust. The net claimants' equity is available for (i) the payments of allowed asbestos-related claims and (ii) operational expenses of the Trust.

Income taxes
Deferred tax assets and liabilities are recorded based on temporary differences between the carrying amounts of assets and liabilities for financial reporting and income tax purposes using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when it is likely that the deferred tax assets may not be realized. The Trust is not subject to state income taxes, and therefore, the Financial Statements do not include any provision or liability for state income taxes. Funds received by the Trust from Christy and from insurance settlements and disbursements paid to settle asbestos claims are not taxable or deductible by the Trust.

The Trustee's estimate of the potential outcome of any uncertain tax issues is subject to management's assessment of relevant risks, facts, and circumstances existing at that time. The Trust uses a more likely than not threshold for financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. To the extent that the Trustee's assessment of such tax position changes, the change in estimate is recorded in the period in which the determination is made. The Trust reports tax-related interest and penalties as a component of income tax expense and operating expenses, respectively. The Trust has recognized no increase in assets or liabilities for unrecognized tax benefits or expense.

Subsequent events
The Trust has evaluated events and transactions subsequent to the date of the Financial Statements for matters requiring recognition or disclosure in the Financial Statements. The accompanying Financial Statements consider events through April 14, 2023, the date on which the Financial Statements were available to be issued.

Note 3 - Investments in marketable securities and certificates of deposit

The Trust measures its investments, at fair value, according to a hierarchy of valuation techniques. The following are the levels of the hierarchy and a brief description of the type of valuation information ("inputs") that qualifies an investment for each level:

Level I - Quoted prices are available in active markets for identical investments as of the reporting date.

Level II - Pricing inputs are other than quoted market prices included in Level I, however, are observable indirectly for the investment.

Level III - Pricing inputs are unobservable for the investment and includes situations where there is little, if any, market activity for the investment. The inputs into the determination of fair value require significant management judgment or estimation. The Trust does not carry any Level III investments.

The following section describes the valuation methodologies the Trust uses to measure its financial assets at fair value.

Certificates of deposit and mutual funds: Valued at the closing price reported on the active market on which the individual securities are traded.

Municipal bonds: Value using the documented trade price if trading in an active market. Otherwise, valued using a metrics system provided by the pricing vendors.

The valuations of the Trust's investments in marketable securities and certificates of deposit by the above fair value hierarchy levels and the corresponding cost of the investments as of December 31, 2022 and 2021, are as follows:

	December 31, 2022			
	Level	Market value	Cost	Unrealized gains (losses), net
Certificates of deposit	I	$ 279,022	$ 279,022	$ -
Mutual funds - equity funds	I	3,636,629	3,072,683	563,946
Municipal bonds	II	7,848,915	7,967,454	(118,539)
		$ 11,764,566	$ 11,319,159	$ 445,407

	December 31, 2021			
	Level	Market value	Cost	Unrealized gains (losses), net
Certificates of deposit	I	$ 277,242	$ 277,242	$ -
Mutual funds - equity funds	I	5,884,709	4,321,815	1,562,894
Municipal bonds	II	12,953,095	12,410,196	542,899
		$ 19,115,046	$ 17,009,253	$ 2,105,793

The net gain (loss) on investments in marketable securities is calculated as follows for the year ended December 31, 2022 and 2021:

	2022	2021
Realized gains (losses), net	$ (500,674)	$ 119,057
Unrealized gains (losses), net	(1,660,385)	278,345
Management fees	(19,242)	(23,328)
Custody fees	(7,276)	(7,016)
Bond amortization	(253,635)	(297,069)
Net gain (loss) in investment securities	$ (2,441,212)	$ 69,989

Maturities of the Trust's debt securities at December 31, 2022 are as follows:

	Level	Market value	Cost	Unrealized gains (losses), net
Due in one year or less	II	$ 115,941	$ 115,740	$ 201
Due after one year through five years	II	2,080,335	2,102,380	(22,045)
Due after five years through ten years	II	4,289,728	4,346,766	(57,038)
Due after ten years through twenty years	II	1,204,288	1,230,375	(26,087)
Due after twenty years	II	158,623	172,193	(13,570)
		$ 7,848,915	$ 7,967,454	$ (118,539)

Note 4 - Taxation

The Trust reports its income to the Internal Revenue Service as a designated settlement fund which is taxed at the highest rate applicable to trusts under Section I(e) of the Code, which was 37% for the years ending December 31, 2022 and 2021.

For net operating losses ("NOLs") created in years beginning after December 31, 2017, the carryforward of NOLs will be limited to a reduction of 80% of modified taxable income without expiration. NOLs prior to January 1, 2018 will carry forward 20 years, and there is no limitation in the reduction of modified taxable income.

The Trust's federal income tax expense (benefit) is calculated as follows for years ended December 31:

	2022	2021
Modified taxable income (loss)	$ (260,949)	$ 37,459
Tax rate	37%	37%
Federal income tax expense (benefit)	(96,551)	13,859
Deferred federal income tax expense (benefit)	(756,502)	102,988
Change in valuation allowance	246,633	-
Income tax expense (benefit), net	$ (606,420)	$ 116,847

Temporary differences between financial reporting income and taxable income generate deferred tax assets and liabilities, as follows for years ended December 31:

	2022	2021
Net operating loss carryforward	$ 411,433	$ 172,723
Valuation allowance	(246,633)	-
Unrealized gain on investments	(164,800)	(779,143)
Net deferred tax liability	$ -	$ (606,420)

At December 31, 2022, the Trust had approximately $1,111,900 of net operating loss carryforwards, with $540,600 expiring in years 2034 to 2037 and $571,300 having no expiration date. The future ability of the Trust to benefit from these carryforwards is uncertain; therefore, management has determined that a valuation allowance for the entire deferred tax asset is necessary since it is more likely than not that the benefits will not be fully realized. The amount of income taxes the Trust pays is subject to ongoing audits by federal authorities.

Note 5 - Trust advisory committee and legal representative

The Trust Agreement sets forth the role and responsibility of the Trust Advisory Committee ("TAC") and Legal Representative ("LR"). The members of the TAC serve in a fiduciary capacity representing all holders of present Asbestos Claims ("Current Claimants"). The Trustee is required to consult with or obtain the consent of the TAC on certain matters identified in the Trust Agreement and the TDP. The TAC is comprised of three attorneys who are engaged by Current Claimants. Members of the Trust Advisory Committee were not reimbursed for any fees or expenses during the period covered by these Financial Statements.

The LR serves in a fiduciary capacity, representing the interests of the individuals who may file an Asbestos Claim in the future, but who at this time are unknown to the Trust ("Future Asbestos Claimants"). His role, in part, is to protect rights of the Future Asbestos Claimants. The Trustee is required to consult with or obtain the consent of the LR on certain matters identified in the Trust Agreement and the TDP.

Note 6 - Claims Resolution Agreement

During 2020, the Trust executed a Claims Resolution Agreement ("Agreement") with a law firm ("Firm") whereby the Trust would transfer $1,500,000 ("First Payment") and an additional $1,500,000 ("Second Payment") for a total of $3,000,000 to a segregated trust account. When the Trust advises the Firm that certain claims of individuals represented by the Firm have been approved for payment in a stated amount, the Firm may withdraw those stated amounts from the trust account for distribution to claimants. During 2020, a total of $3,000,000 was transferred to the account. During the years ended December 31, 2022 and 2021, a total of $57,420 and $354,960, respectively, was disbursed to claimants. At December 31, 2022 and 2021, a balance of $209,620 and $267,040, respectively, remained in the account, which is included in restricted cash in the statement of net claimants equity.

CohnReznick
ADVISORY • ASSURANCE • TAX

Independent Member of Nexia International

cohnreznick.com

Christy Refractories Asbestos Personal Injury Trust

Report of Asbestos Claim Activity and Disposition during Period from January 1, 2022 through December 31, 2022

Type of Claim	Number of Claims Filed	Number of Claims Approved for Payment	Number of Claims Withdrawn or Rejected	Liquidated Value of Approved Claims	Number of Approved Claims Paid	Amount Paid on Approved Claims after Application of Payment Percentage
Pre-Petition Liquidated Claims	0	0	0	$0	61	$576,000.00
Category A Claims (Disease Levels IV – VIII)	473	14	563	$801,993	463	$4,386,537
Category B Claims (Disease Levels II and III)	43	2	39	$18,000	35	$35,950.00
Disease Level I Claims	13	0	13	$0	0	$0
Unspecified Disease Level Claims	34	0	33	$0	0	$0

* The Payment Percentage does not apply to Disease Level I claims

Christy Refractories Asbestos Personal Injury Trust

Report of Compensation and Expense Reimbursement
(January 1, 2022 through December 31, 2022)

	Compensation	Expense Reimbursement
Alan B. Rich (Trustee)	$129,951	$2
Dean M. Trafelet (Futures Representative)	$2,625	$-0-

{BRAUER/002/00026131.DOC/ }

Published by AsbestosClaims.Law
asbestosclaims.law/library/13793/21